Salubris(SZ:002294) 智通财经网·2025-08-28 08:15Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial application of its innovative small molecule drug SAL0140, which targets uncontrolled hypertension and chronic kidney disease [1] Group 1: Product Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company [1] - The drug is currently in Phase I clinical trials for the indication of uncontrolled hypertension [1] - If successful, SAL0140 is expected to provide new treatment options for patients with uncontrolled hypertension and chronic kidney disease, addressing unmet clinical needs [1] Group 2: Market Potential - The development of SAL0140 will enrich the company's pipeline of innovative products in the chronic disease sector [1] - The targeted indications for SAL0140 include resistant hypertension and chronic kidney disease, which represent significant market opportunities [1]